Viking Therapeutics Inc. VKTX
$29.74
▲ +0.49% 24H
About
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical trials for obesity, with formulations in both subcutaneous injectable…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees59
TickerVKTX
Statistics
Market Cap$3.45B
Revenue (TTM)$0
Net Income-$359.6M
Net Margin—
EPS$-3.19
P/E-9.02
P/S—
P/B5.14
EV/EBITDA-6.66
ROE-70.0%
Dividend Yield—
Price$29.74
Data: Twelve Data · Revenue = mcap / P/S